A Phase 3 interventional study of NOV03 and Placebo in Dry Eye Disease (DED), sponsored by Bausch & Lomb Incorporated. Completed at 29 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-23.
Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing perfluorohexyloctane in Dry Eye Syndromes — 1 open to participants now, 2 under way, none of them phase 3. perfluorohexyloctane · Dry Eye Syndromes.
Among the 13 studies testing perfluorohexyloctane in Dry Eye Syndromes, this one is the 2nd largest by enrollment, is one of 3 that started in 2020, is one of 4 in phase 3, and was the 2nd registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →1 of the 13 studies testing perfluorohexyloctane in Dry Eye Syndromes is open now, in 1 country. Recruiting first, the newest first:
Beijing Tongren Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
perfluorohexyloctane: first FDA approval 2023 (MIEBO). What it is approved for, and how studies give it, is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 3 started in 2020.
This study's enrollment of 599 is above the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 216 across the 13 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 13 have an industry lead sponsor. The 5 most frequent:
This study is registered under Bausch & Lomb Incorporated, one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch & Lomb Incorporated is the lead sponsor of 223 studies on the registry; 5 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 41 (80%) have results posted.
25 studies in Dry Eye Syndromes by Bausch Health Companies Inc.: 1 open now, 2 under way, none of them phase 3. Of 21 finished, 16 (76%) have results posted.
Among the 25 studies in Dry Eye Syndromes by Bausch Health Companies Inc., this one is the 3rd largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2020, is one of 5 in phase 3, and was the 15th registered.
Bausch Health Companies Inc.’s Dry Eye Syndromes studies by the year they started, since 2005.
1 of the studies testing perfluorohexyloctane in Dry Eye Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07679685Beijing Tongren HospitalPerfluorohexyloctane Eye Drops vs. Sodium Hyaluronate for Video Display Terminal-Associated Dry Eye | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing perfluorohexyloctane in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bausch Health Companies Inc.’s 25 in Dry Eye Syndromes:
This tab as a report to print or save as PDF → With an account.
This trial will evaluate the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100% Perfluorohexyloctance solution 4 times daily (QID)
Drug: NOV03
Saline solution (0.6% sodium chloride solution) 4 times daily (QID)
Drug: Placebo
100% Perfluorohexyloctane
Saline solution (0.6% sodium chloride solution)
Change From Baseline (CFB) in Total Corneal Fluorescein Staining (tCFS) at Day 57
Corneal Fluorescein Staining (tCFS) is graded based on the NEI scale. The NEI scale divides the cornea in 5 subregions: central, inferior, superior, nasal, temporal. The score for each region ranges from 0-3; 0 corresponds to no staining, 3 corresponds to maximum staining. The total score is the sum of the 5 subregions ranging from 0-15.
Time frame: Assessed from Baseline to Day 57
Change From Baseline of Dryness Score at Day 57
Dryness Score is rated on a visual analogue scale (VAS) ranging from 0-100; 0 corresponds to no discomfort and 100 to maximum discomfort).
Time frame: Assessed from Baseline to Day 57
| Milestone | NOV03 4 Times Daily (QID) | Placebo 4 Times Daily (QID) |
|---|---|---|
| Started | 303 | 294 |
| Completed | 289 | 279 |
| Not completed | 14 | 15 |
| Withdrew: Withdrawal by subject | 6 | 5 |
| Withdrew: Lost to follow-up | 2 | 5 |
| Withdrew: Discontinued | 4 | 2 |
| Withdrew: Adverse event | 1 | 3 |
| Withdrew: Protocol violation | 1 | 0 |
Corneal Fluorescein Staining (tCFS) is graded based on the NEI scale. The NEI scale divides the cornea in 5 subregions: central, inferior, superior, nasal, temporal. The score for each region ranges from 0-3; 0 corresponds to no staining, 3 corresponds to maximum staining. The total score is the sum of the 5 subregions ranging from 0-15.
| units on a scale | NOV03 4 Times Daily (QID) | Placebo 4 Times Daily (QID) |
|---|---|---|
| Change From Baseline (CFB) in Total Corneal Fluorescein Staining (tCFS) at Day 57 | -2.0 ± 2.6 | -1.0 ± 2.7 |
Dryness Score is rated on a visual analogue scale (VAS) ranging from 0-100; 0 corresponds to no discomfort and 100 to maximum discomfort).
| units on a scale | NOV03 4 Times Daily (QID) | Placebo 4 Times Daily (QID) |
|---|---|---|
| Change From Baseline of Dryness Score at Day 57 | -27.4 ± 27.9 | -19.7 ± 26.7 |
Collected over Assessed throughout the study, approximately 8 weeks.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NOV03 4 Times Daily (QID) | 0/303 (0%) | 0/303 (0%) | 16/303 (5.3%) |
| Placebo 4 Times Daily (QID) | 0/294 (0%) | 0/294 (0%) | 11/294 (3.7%) |
| Event | NOV03 4 Times Daily (QID) | Placebo 4 Times Daily (QID) |
|---|---|---|
| Vision blurredEye disorders | 9/303 | 1/294 |
| Conjunctival haemorrhageEye disorders | 1/303 | 4/294 |
| Instillation site painEye disorders | 3/303 | 3/294 |
| Punctate keratitisEye disorders | 0/303 | 3/294 |
| Eye dischargeEye disorders | 3/303 | 0/294 |
| Age, Continuous(years) | NOV03 4 Times Daily (QID) | Placebo 4 Times Daily (QID) | Total |
|---|---|---|---|
| Mean | 60.3 ± 14.23 | 61.6 ± 13.57 | 60.9 ± 13.91 |
| Sex: Female, Male(Participants) | NOV03 4 Times Daily (QID) | Placebo 4 Times Daily (QID) | Total |
|---|---|---|---|
| Female | 219 | 214 | 433 |
| Male | 84 | 80 | 164 |
| Ethnicity (NIH/OMB)(Participants) | NOV03 4 Times Daily (QID) | Placebo 4 Times Daily (QID) | Total |
|---|---|---|---|
| Hispanic or Latino | 43 | 51 | 94 |
| Not Hispanic or Latino | 260 | 243 | 503 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2020 to primary completion in Mar 2021, 7 months.
Results were first posted in Oct 2024, 3 years 7 months after primary completion. A results delay was requested in Mar 2022.
Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 7 months is below that.
Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Perfluorohexyloctane